Sun Pharma.Inds.

{
  "main_header": {
    "sid": 948699,
    "name": "Sun Pharma.Inds.",
    "stock_name": "Sun Pharma.Inds.",
    "full_name": "Sun Pharmaceutical Industries Ltd",
    "name_url": "stocks-analysis/sun-pharmainds",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,949.00",
    "chg": 5,
    "chgp": "0.26%",
    "dir": 1,
    "prev_price": "1,944.00",
    "mcapval": "467,390.00 Cr",
    "mcap": "Large Cap",
    "scripcode": 524715,
    "symbol": "SUNPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE044A01036",
    "curr_date": "Aug 07, 04:01 PM",
    "curr_time": "16:39 PM",
    "last_traded_at": "Aug 07, 04:01 PM IST",
    "bse_nse_vol": "28.78 lacs",
    "exc_status": "Active",
    "traded_date": "Aug 07, 2026",
    "traded_date_str": "2026 08 07",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sun-pharmainds-948699-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "text": "Part of MojoOne Strategy",
      "type": "MS",
      "url": "https://www.marketsmojo.com/mojostocks#!#top10",
      "ismore": 0,
      "all_data": [],
      "is_blur": 1,
      "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sun-pharmainds-948699-0&utm_source=Spage_Score_PartofStrategies"
    }
  },
  "news": {
    "results": [
      {
        "title": "P/E at 36.92 vs Industry's 36.68: What the Data Shows for Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-navigating-nifty-50-membership-and-institutional-dynamics-4141272",
        "imagepath": "",
        "date": "2026-08-07 09:21:55",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: P/E in Context</strong></p>\n                <p>The current P/E of <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a> stands at 36.92, marginally above the Pharmaceuticals &amp; Biotechnology industry average of 36.68. This slight premium suggests that the market is pricing in expectations broadly in line with sector peers, neither significantly overvalued nor undervalued. Given the large-cap status and a market capitalisation of approximately ₹4,67,798.34 crores, this valuation reflects a mature company with stable earnings prospects. The near parity in P/E ratios raises the question of whether the premium is justified by operational performance or if it merely reflects sector-wid..."
      },
      {
        "title": "P/E at 37.01 vs Industry's 36.91: What the Data Shows for Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-nifty-50-membership-and-institutional-dynamics-shape-market-outlook-4139463",
        "imagepath": "",
        "date": "2026-08-06 09:21:20",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Slight Premium Reflects Sector Alignment</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a> trades at a P/E of 37.01, just above the Pharmaceuticals & Biotechnology industry average of 36.91. This near-parity suggests that the market values the company in line with its peers, reflecting neither a significant premium nor discount. The marginal premium could be attributed to the company’s large-cap status and its consistent earnings growth over recent years. However, this valuation does not imply an excessive stretch relative to the sector, which has seen mixed results recently — 7 stocks positive, 5 flat, and 1 negative among 13 reporting so far. Inv..."
      },
      {
        "title": "P/E at 37.22 vs Industry's 36.85: What the Data Shows for Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-navigating-nifty-50-membership-and-institutional-dynamics-4137405",
        "imagepath": "",
        "date": "2026-08-05 09:20:49",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Slight Premium Reflecting Sector Confidence</strong></p>\n                <p>The current P/E of 37.22 for <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a> represents a modest premium of approximately 1% over the industry average of 36.85. This premium suggests that investors are willing to pay slightly more for the stock relative to its peers, potentially reflecting confidence in its earnings stability or growth prospects. However, the premium is not excessive, indicating that valuation remains broadly in line with sector norms. This contrasts with some large-cap pharmaceuticals that trade at multiples significantly above industry averages, signalling either overvaluation or exce..."
      },
      {
        "title": "Sun Pharmaceutical Industries Ltd is Rated Buy",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sun-pharmaceutical-industries-ltd-is-rated-buy-4134893",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/SunPharmaceutic_mojoScore_4134893.png",
        "date": "2026-08-04 10:10:44",
        "description": "Sun Pharmaceutical Industries Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 August 2026, providing investors with the most up-to-date insight into the company’s performance and outlook."
      },
      {
        "title": "Sun Pharmaceutical Industries Ltd: Valuation Shift Signals Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-valuation-shift-signals-renewed-price-attractiveness-4134403",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/SunPharmaceutic_valuationdot_4134403.png",
        "date": "2026-08-04 08:01:40",
        "description": "Sun Pharmaceutical Industries Ltd has witnessed a notable change in its valuation parameters, moving from a very expensive to an expensive rating. This shift, driven primarily by adjustments in its price-to-earnings and price-to-book value ratios, suggests a recalibration of price attractiveness amid a competitive pharmaceutical sector landscape."
      },
      {
        "title": "Rs 1,940 Puts — 0.5% Below Current Price — Draw 2,707 Contracts on Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-sees-heavy-put-option-activity-amid-bearish-hedging-ahead-of-august-expiry-4133346",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/SunPharmaceutic_most_active_stocks_puts_4133346.png",
        "date": "2026-08-03 10:00:10",
        "description": "Rs 1,940 put options on Sun Pharmaceutical Industries Ltd attracted 2,707 contracts on 3 August 2026, just below the stock’s closing price of Rs 1,950. This surge in put activity invites a closer look at whether it signals protective hedging, bearish positioning, or put writing amid a stock trading near its 52-week high."
      },
      {
        "title": "P/E at 38.29 vs Industry's 37.19: What the Data Shows for Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-navigating-nifty-50-membership-and-institutional-dynamics-4133123",
        "imagepath": "",
        "date": "2026-08-03 09:20:57",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Premium Amidst Sector Parity</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a> trades at a P/E of 38.29, slightly above the Pharmaceuticals & Biotechnology industry average of 37.19. This premium, though not extreme, suggests investors are willing to pay a bit more for the company’s earnings relative to its peers. The market capitalisation stands at a substantial ₹4,70,977.46 crores, underscoring its large-cap stature within the sector. Such a valuation premium often reflects expectations of superior earnings growth or stability, but it also raises questions about whether the premium is justified given recent performance trends — <a href=\"https://w..."
      },
      {
        "title": "Sun Pharmaceutical Industries Ltd Gains 2.49%: 5 Key Factors Driving the Week’s Rally",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-gains-249-5-key-factors-driving-the-weeks-rally-4131590",
        "imagepath": "",
        "date": "2026-08-01 14:05:29",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>27 Jul:</strong> New 52-week and all-time high at Rs.1,976.4</p>\n                    <p><strong>28 Jul:</strong> Fresh 52-week and all-time high at Rs.1,988</p>\n                    <p><strong>29 Jul:</strong> Continued rally to Rs.1,993.4, marking another 52-week high</p>\n                    <p><strong>30 Jul:</strong> New peak at Rs.2,009.85, surpassing Rs.2,000 milestone</p>\n                    <p><strong>31 Jul:</strong> Week closes at Rs.1,989.35, just below the high with a slight dip</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,973.50</div></di..."
      },
      {
        "title": "Sun Pharma Q1 FY27: Strong Profit Growth Masks Margin Pressure Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/sun-pharma-q1-fy27-strong-profit-growth-masks-margin-pressure-concerns-4130753",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/SunPharmaceutic_quaterlyResult_4130753.png",
        "date": "2026-07-31 20:47:15",
        "description": "Sun Pharmaceutical Industries Ltd., India's largest pharmaceutical company and the fourth-largest global specialty generic player, reported a robust 27.04% year-on-year surge in consolidated net profit to ₹2,894.79 crores for Q1 FY27 (June 2026 quarter), up from ₹2,278.63 crores in the corresponding quarter last year. On a sequential basis, the company posted a healthy 6.66% quarter-on-quarter growth from ₹2,714.03 crores in Q4 FY26. The stock, with a market capitalisation of ₹4,82,770 crores, closed at ₹1,989.35 on July 31, 2026, down 0.57% on the day following the results announcement."
      }
    ],
    "total": 1237,
    "sid": "948699",
    "stock_news_url": "https://www.marketsmojo.com/news/sun-pharmaceutical-industries-948699"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Credit Rating",
      "datetime": "05-Aug-2026",
      "details": "Update on Credit Rating",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "05-Aug-2026",
      "details": "Intimation of Schedule of Analyst/Institutional Investor Meeting",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "01-Aug-2026",
      "details": "Newspaper Advertisement",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Sun Pharmaceutical Industries Ltd has declared <strong>500%</strong> dividend, ex-date: 07 Jul 26",
          "dt": "2026-07-07",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Sun Pharmaceutical Industries Ltd has announced <strong>1:5</strong> stock split, ex-date: 25 Nov 10",
          "dt": "2010-11-25",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Sun Pharmaceutical Industries Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 29 Jul 13",
          "dt": "2013-07-29",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

P/E at 36.92 vs Industry's 36.68: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-08-07 09:21:55

Valuation Picture: P/E in Context

The current P/E of Sun Pharmaceutical Industries Ltd stands at 36.92, marginally above the Pharmaceuticals & Biotechnology industry average of 36.68. This slight premium suggests that the market is pricing in expectations broadly in line with sector peers, neither significantly overvalued nor undervalued. Given the large-cap status and a market capitalisation of approximately ₹4,67,798.34 crores, this valuation reflects a mature company with stable earnings prospects. The near parity in P/E ratios raises the question of whether the premium is justified by operational performance or if it merely reflects sector-wid...

Read full news article

P/E at 37.01 vs Industry's 36.91: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-08-06 09:21:20

Valuation Picture: Slight Premium Reflects Sector Alignment

Sun Pharmaceutical Industries Ltd trades at a P/E of 37.01, just above the Pharmaceuticals & Biotechnology industry average of 36.91. This near-parity suggests that the market values the company in line with its peers, reflecting neither a significant premium nor discount. The marginal premium could be attributed to the company’s large-cap status and its consistent earnings growth over recent years. However, this valuation does not imply an excessive stretch relative to the sector, which has seen mixed results recently — 7 stocks positive, 5 flat, and 1 negative among 13 reporting so far. Inv...

Read full news article

P/E at 37.22 vs Industry's 36.85: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-08-05 09:20:49

Valuation Picture: Slight Premium Reflecting Sector Confidence

The current P/E of 37.22 for Sun Pharmaceutical Industries Ltd represents a modest premium of approximately 1% over the industry average of 36.85. This premium suggests that investors are willing to pay slightly more for the stock relative to its peers, potentially reflecting confidence in its earnings stability or growth prospects. However, the premium is not excessive, indicating that valuation remains broadly in line with sector norms. This contrasts with some large-cap pharmaceuticals that trade at multiples significantly above industry averages, signalling either overvaluation or exce...

Read full news article

Sun Pharmaceutical Industries Ltd is Rated Buy

2026-08-04 10:10:44

Sun Pharmaceutical Industries Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 August 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Read full news article

Sun Pharmaceutical Industries Ltd: Valuation Shift Signals Renewed Price Attractiveness

2026-08-04 08:01:40

Sun Pharmaceutical Industries Ltd has witnessed a notable change in its valuation parameters, moving from a very expensive to an expensive rating. This shift, driven primarily by adjustments in its price-to-earnings and price-to-book value ratios, suggests a recalibration of price attractiveness amid a competitive pharmaceutical sector landscape.

Read full news article

Rs 1,940 Puts — 0.5% Below Current Price — Draw 2,707 Contracts on Sun Pharmaceutical Industries Ltd

2026-08-03 10:00:10

Rs 1,940 put options on Sun Pharmaceutical Industries Ltd attracted 2,707 contracts on 3 August 2026, just below the stock’s closing price of Rs 1,950. This surge in put activity invites a closer look at whether it signals protective hedging, bearish positioning, or put writing amid a stock trading near its 52-week high.

Read full news article

P/E at 38.29 vs Industry's 37.19: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-08-03 09:20:57

Valuation Picture: Premium Amidst Sector Parity

Sun Pharmaceutical Industries Ltd trades at a P/E of 38.29, slightly above the Pharmaceuticals & Biotechnology industry average of 37.19. This premium, though not extreme, suggests investors are willing to pay a bit more for the company’s earnings relative to its peers. The market capitalisation stands at a substantial ₹4,70,977.46 crores, underscoring its large-cap stature within the sector. Such a valuation premium often reflects expectations of superior earnings growth or stability, but it also raises questions about whether the premium is justified given recent performance trends — Read full news article

Sun Pharmaceutical Industries Ltd Gains 2.49%: 5 Key Factors Driving the Week’s Rally

2026-08-01 14:05:29

Key Events This Week

27 Jul: New 52-week and all-time high at Rs.1,976.4

28 Jul: Fresh 52-week and all-time high at Rs.1,988

29 Jul: Continued rally to Rs.1,993.4, marking another 52-week high

30 Jul: New peak at Rs.2,009.85, surpassing Rs.2,000 milestone

31 Jul: Week closes at Rs.1,989.35, just below the high with a slight dip

Week Open

Rs.1,973.50

Read full news article

Sun Pharma Q1 FY27: Strong Profit Growth Masks Margin Pressure Concerns

2026-07-31 20:47:15

Sun Pharmaceutical Industries Ltd., India's largest pharmaceutical company and the fourth-largest global specialty generic player, reported a robust 27.04% year-on-year surge in consolidated net profit to ₹2,894.79 crores for Q1 FY27 (June 2026 quarter), up from ₹2,278.63 crores in the corresponding quarter last year. On a sequential basis, the company posted a healthy 6.66% quarter-on-quarter growth from ₹2,714.03 crores in Q4 FY26. The stock, with a market capitalisation of ₹4,82,770 crores, closed at ₹1,989.35 on July 31, 2026, down 0.57% on the day following the results announcement.

Read full news article

View All News